Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Candel Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 21 | 20 | −1 |
| Shares | 5.48M | 5.37M | −108.2K (−2.0%) |
| Value | $7.44M | $6.77M | −$671.1K (−9.0%) |
New holders (2)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 118,612 | $149.5K | 0.00% |
| Royal Bank of Canada | 163 | $0 | 0.00% |
Sold out (3)
Institutions that held Candel Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Citadel Advisors LLC | 47,174 | $64.6K |
| Ergoteles LLC | 11,416 | $15.6K |
| Quent Capital, LLC | 182 | $246 |